Bruker Corporation $BRKR Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC cut its stake in Bruker Corporation (NASDAQ:BRKR) by 8.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 126,630 shares of the medical research company’s stock after selling 12,174 shares during the quarter. Peregrine Capital Management LLC owned about 0.08% of Bruker worth $4,574,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Los Angeles Capital Management LLC purchased a new stake in shares of Bruker in the fourth quarter valued at about $26,000. Allworth Financial LP raised its stake in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the period. Parallel Advisors LLC raised its stake in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the period. Summit Securities Group LLC acquired a new position in Bruker in the 4th quarter valued at about $50,000. Finally, Covestor Ltd boosted its holdings in Bruker by 304.6% in the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,066 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Insider Transactions at Bruker

In other news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 27.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BRKR shares. Guggenheim raised their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday. Wolfe Research initiated coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating on the stock. Citigroup increased their price objective on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. TD Cowen raised their target price on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $54.54.

Bruker Price Performance

Shares of BRKR opened at $60.64 on Thursday. The firm has a 50-day simple moving average of $49.69 and a two-hundred day simple moving average of $44.79. The stock has a market cap of $9.23 billion, a PE ratio of -252.67, a P/E/G ratio of 1.93 and a beta of 1.29. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts forecast that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.